Keymed Biosciences reported interim results for the six months ended June 30, 2026 with total revenue of RMB617 million. Sales of its core product Kangyueda rose 132% YoY to RMB393 million, indicating strong product momentum. Overall, the update is modestly positive for the company’s near-term outlook and fundamental trajectory.
Keymed Biosciences reported interim results for the six months ended June 30, 2026 with total revenue of RMB617 million. Sales of its core product Kangyueda rose 132% YoY to RMB393 million, indicating strong product momentum. Overall, the update is modestly positive for the company’s near-term outlook and fundamental trajectory.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
